Clinical Report: Safety Profile of a 30-Minute Intravenous Isatuximab Infusion
Overview
This study evaluates the safety of a rapid 30-minute intravenous infusion of isatuximab in patients with multiple myeloma. The findings indicate a low incidence of infusion-related reactions (IRRs).
Background
Isatuximab is a key treatment for multiple myeloma, traditionally requiring a lengthy infusion time of at least 75 minutes. The burden of this extended administration impacts patient experience and healthcare resources. This study presents data on a rapid 30-minute infusion protocol.
Data Highlights
Parameter
Value
Total Patients
103
Median Age
66 years
Infusions Administered
1,344
IRR per Patient Rate
0.97% (95% CI: 0.17%–5.30%)
IRR per Infusion Rate
0.074% (95% CI: 0.013%–0.420%)
Cumulative Chair Time Savings
1,008 hours
Key Findings
Only 1 infusion-related reaction (IRR) was recorded among 1,344 rapid infusions.
Per-patient IRR rate was 0.97%, while per-infusion rate was 0.074%.
21 out of 22 patients with prior IRRs completed the rapid infusion protocol without reverting to standard rates.
No patients permanently discontinued isatuximab due to IRRs.
Clinical Implications
The findings suggest that a rapid 30-minute infusion of isatuximab is safe, even for patients with a history of IRRs. This approach can enhance patient throughput and reduce resource utilization in clinical settings.
Conclusion
The study presents data on a rapid 30-minute infusion protocol for isatuximab in multiple myeloma.
